Differences in the molecular mechanisms of adrenocortical tumorigenesis between children and adults

Molecular and Cellular Endocrinology

Volumn 351, Issue 1, 2012, Pages 52-57

  Faria, André M ^a   Almeida, Madson Q ^a,b  

^a Unidade de Suprarrenal e Endocrinologia do Desenvolvimento   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adrenocortical tumors; Children; IGF1R; IGF2; P53; SF1

Indexed keywords

SOMATOMEDIN B; SOMATOMEDIN C RECEPTOR; STEROIDOGENIC FACTOR 1;

ADRENAL CORTEX CARCINOMA; AGE DISTRIBUTION; BENIGN TUMOR; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CHROMOSOME 17P; DIFFERENTIAL DIAGNOSIS; GENE DOSAGE; GENE FUNCTION; GENE LOCUS; GENE OVEREXPRESSION; HETEROZYGOSITY LOSS; HUMAN; IGF1R GENE; IGF2 GENE; MARKER GENE; MOLECULAR PATHOLOGY; MUTATIONAL ANALYSIS; OUTCOME ASSESSMENT; PHENOTYPE; PRIORITY JOURNAL; RECURRENCE FREE SURVIVAL; REVIEW; SF1 GENE; SIGNAL TRANSDUCTION; SOMATIC MUTATION; TUMOR SUPPRESSOR GENE;

ADOLESCENT; ADRENAL CORTEX NEOPLASMS; ADULT; AGE FACTORS; AMINO ACID SUBSTITUTION; CELL TRANSFORMATION, NEOPLASTIC; CHILD; CHILD, PRESCHOOL; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GERM-LINE MUTATION; HUMANS; INSULIN-LIKE GROWTH FACTOR II; MALE; MUTATION, MISSENSE; RECEPTOR, IGF TYPE 1; RECURRENCE; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84857122958     PISSN: 03037207     EISSN: 18728057     Source Type: Journal    
DOI: 10.1016/j.mce.2011.09.040     Document Type: Review

References (59)

1. Abiven G., Coste J., Groussin L., Anract P., Tissier F., Legmann P., Dousset B., Bertagna X., Bertherat J. Clinical and biological features in the prognosis of adrenocortical cancer: poor outcome of cortisol-secreting tumors in a series of 202 consecutive patients. J. Clin. Endocrinol. Metab. 2006, 91:2650-2655.
2. Achatz M.I., Olivier M., Calvez F.L., Martel-Planche G., Lopes A., Rossi B.M., Ashton-Prolla P., Giugliani R., Palmero E.I., Vargas F.R., Rocha J.C., Vettore A.L., Hainaut P. The TP53 mutation, R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in Brazilian families. Cancer Lett. 2007, 245:96-102.
3. Allolio B., Fassnacht M. Clinical review: adrenocortical carcinoma: clinical update. J. Clin. Endocrinol. Metab. 2006, 91:2027-2037.
4. Almeida M.Q., Latronico A.C. The molecular pathogenesis of childhood adrenocortical tumors. Horm. Metab. Res. 2007, 39:461-466.
5. Almeida M.Q., Fragoso M.C., Lotfi C.F., Santos M.G., Nishi M.Y., Costa M.H., Lerario A.M., Maciel C.C., Mattos G.E., Jorge A.A., Mendonca B.B., Latronico A.C. Expression of insulin-like growth factor-II and its receptor in pediatric and adult adrenocortical tumors. J. Clin. Endocrinol. Metab. 2008, 93:3524-3531.
6. Almeida M.Q., Soares I.C., Ribeiro T.C., Fragoso M.C., Marins L.V., Wakamatsu A., Ressio R.A., Nishi M.Y., Jorge A.A., Lerario A.M., Alves V.A., Mendonca B.B., Latronico A.C. Steroidogenic factor 1 overexpression and gene amplification are more frequent in adrenocortical tumors from children than from adults. J. Clin. Endocrinol. Metab. 2010, 95:1458-1462.
7. Aubert S., Wacrenier A., Leroy X., Devos P., Carnaille B., Proye C., Wemeau J.L., Lecomte-Houcke M., Leteurtre E. Weiss system revisited: a clinicopathologic and immunohistochemical study of 49 adrenocortical tumors. Am. J. Surg. Pathol. 2002, 26:1612-1619.
8. Barlaskar F.M., Spalding A.C., Heaton J.H., Kuick R., Kim A.C., Thomas D.G., Giordano T.J., Ben-Josef E., Hammer G.D. Preclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma. J. Clin. Endocrinol. Metab. 2009, 94:204-212.
9. Beuschlein F., Mutch C., Bavers D.L., Ulrich-Lai Y.M., Engeland W.C., Keegan C., Hammer G.D. Steroidogenic factor-1 is essential for compensatory adrenal growth following unilateral adrenalectomy. Endocrinology 2002, 143:3122-3135.
10. Blons H., Laurent-Puig P. TP53 and head and neck neoplasms. Hum. Mutat. 2003, 21:252-257.
11. Brosh R., Rotter V. When mutants gain new powers: news from the mutant p53 field. Nat. Rev. Cancer 2009, 9:701-713.
12. Chompret A., Brugieres L., Ronsin M., Gardes M., Dessarps-Freichey F., Abel A., Hua D., Ligot L., Dondon M.G., Bressac-de Paillerets B., Frebourg T., Lemerle J., Bonaiti-Pellie C., Feunteun J. P53 germline mutations in childhood cancers and cancer risk for carrier individuals. Br. J. Cancer 2000, 82:1932-1937.
13. de Fraipont F., El Atifi M., Cherradi N., Le Moigne G., Defaye G., Houlgatte R., Bertherat J., Bertagna X., Plouin P.F., Baudin E., Berger F., Gicquel C., Chabre O., Feige J.J. Gene expression profiling of human adrenocortical tumors using complementary deoxyribonucleic acid microarrays identifies several candidate genes as markers of malignancy. J. Clin. Endocrinol. Metab. 2005, 90:1819-1829.
14. de Reynies A., Assie G., Rickman D.S., Tissier F., Groussin L., Rene-Corail F., Dousset B., Bertagna X., Clauser E., Bertherat J. Gene expression profiling reveals a new classification of adrenocortical tumors and identifies molecular predictors of malignancy and survival. J. Clin. Oncol. 2009, 27:1108-1115.
15. Doghman M., Karpova T., Rodrigues G.A., Arhatte M., De Moura J., Cavalli L.R., Virolle V., Barbry P., Zambetti G.P., Figueiredo B.C., Heckert L.L., Lalli E. Increased steroidogenic factor-1 dosage triggers adrenocortical cell proliferation and cancer. Mol. Endocrinol. 2007, 21:2968-2987.
16. Doghman M., El Wakil A., Cardinaud B., Thomas E., Wang J., Zhao W., Peralta-Del Valle M.H., Figueiredo B.C., Zambetti G.P., Lalli E. Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Cancer Res. 2010, 70:4666-4675.
17. Fassnacht M., Allolio B. Clinical management of adrenocortical carcinoma. Best Pract. Res. Clin. Endocrinol. Metab. 2009, 23:273-289.
18. Fassnacht M., Johanssen S., Quinkler M., Bucsky P., Willenberg H.S., Beuschlein F., Terzolo M., Mueller H.H., Hahner S., Allolio B. Limited prognostic value of the 2004 International Union against cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM Classification. Cancer 2009, 115:243-250.
19. Figueiredo B.C., Stratakis C.A., Sandrini R., DeLacerda L., Pianovsky M.A., Giatzakis C., Young H.M., Haddad B.R. Comparative genomic hybridization analysis of adrenocortical tumors of childhood. J. Clin. Endocrinol. Metab. 1999, 84:1116-1121.
20. Figueiredo B.C., Cavalli L.R., Pianovski M.A., Lalli E., Sandrini R., Ribeiro R.C., Zambetti G., DeLacerda L., Rodrigues G.A., Haddad B.R. Amplification of the steroidogenic factor 1 gene in childhood adrenocortical tumors. J. Clin. Endocrinol. Metab. 2005, 90:615-619.
21. Garritano S., Gemignani F., Palmero E.I., Olivier M., Martel-Planche G., Le Calvez-Kelm F., Brugieres L., Vargas F.R., Brentani R.R., Ashton-Prolla P., Landi S., Tavtigian S.V., Hainaut P., Achatz M.I. Detailed haplotype analysis at the TP53 locus in p.R337H mutation carriers in the population of Southern Brazil: evidence for a founder effect. Hum. Mutat. 2010, 31:143-150.
22. Gicquel C., Bertagna X., Schneid H., Francillard-Leblond M., Luton J.P., Girard F., Le Bouc Y. Rearrangements at the 11p15 locus and overexpression of insulin-like growth factor-II gene in sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 1994, 78:1444-1453.
23. Gicquel C., Raffin-Sanson M.L., Gaston V., Bertagna X., Plouin P.F., Schlumberger M., Louvel A., Luton J.P., Le Bouc Y. Structural and functional abnormalities at 11p15 are associated with the malignant phenotype in sporadic adrenocortical tumors: study on a series of 82 tumors. J. Clin. Endocrinol. Metab. 1997, 82:2559-2565.
24. Gicquel C., Bertagna X., Gaston V., Coste J., Louvel A., Baudin E., Bertherat J., Chapuis Y., Duclos J.M., Schlumberger M., Plouin P.F., Luton J.P., Le Bouc Y. Molecular markers and long-term recurrences in a large cohort of patients with sporadic adrenocortical tumors. Cancer Res. 2001, 61:6762-6767.
25. Giordano T.J., Thomas D.G., Kuick R., Lizyness M., Misek D.E., Smith A.L., Sanders D., Aljundi R.T., Gauger P.G., Thompson N.W., Taylor J.M., Hanash S.M. Distinct transcriptional profiles of adrenocortical tumors uncovered by DNA microarray analysis. Am. J. Pathol. 2003, 162:521-531.
26. Giordano T.J., Kuick R., Else T., Gauger P.G., Vinco M., Bauersfeld J., Sanders D., Thomas D.G., Doherty G., Hammer G. Molecular classification and prognostication of adrenocortical tumors by transcriptome profiling. Clin. Cancer Res. 2009, 15:668-676.
27. Haluska P., Worden F., Olmos D., Yin D., Schteingart D., Batzel G.N., Paccagnella M.L., de Bono J.S., Gualberto A., Hammer G.D. Safety, tolerability, and pharmacokinetics of the anti-IGF-1R monoclonal antibody figitumumab in patients with refractory adrenocortical carcinoma. Cancer Chemother. Pharmacol. 2010, 65:765-773.
28. Iacopetta B. TP53 mutation in colorectal cancer. Hum. Mutat. 2003, 21:271-276.
29. Ilvesmaki V., Blum W.F., Voutilainen R. Insulin-like growth factor binding proteins in the human adrenal gland. Mol. Cell. Endocrinol. 1993, 97:71-79.
30. Ishimoto H., Jaffe R.B. Development and function of the human fetal adrenal cortex: a key component in the feto-placental unit. Endocr. Rev. 2011, 32:317-355.
31. Latronico A.C., Chrousos G.P. Extensive personal experience: adrenocortical tumors. J. Clin. Endocrinol. Metab. 1997, 82:1317-1324.
32. Latronico A.C., Pinto E.M., Domenice S., Fragoso M.C., Martin R.M., Zerbini M.C., Lucon A.M., Mendonca B.B. An inherited mutation outside the highly conserved DNA-binding domain of the p53 tumor suppressor protein in children and adults with sporadic adrenocortical tumors. J. Clin. Endocrinol. Metab. 2001, 86:4970-4973.
33. Lau S.K., Weiss L.M. The Weiss system for evaluating adrenocortical neoplasms: 25years later. Hum. Pathol. 2009, 40:757-768.
34. Libe R., Groussin L., Tissier F., Elie C., Rene-Corail F., Fratticci A., Jullian E., Beck-Peccoz P., Bertagna X., Gicquel C., Bertherat J. Somatic TP53 mutations are relatively rare among adrenocortical cancers with the frequent 17p13 loss of heterozygosity. Clin. Cancer Res. 2007, 13:844-850.
35. Logie A., Boulle N., Gaston V., Perin L., Boudou P., Le Bouc Y., Gicquel C. Autocrine role of IGF-II in proliferation of human adrenocortical carcinoma NCI H295R cell line. J. Mol. Endocrinol. 1999, 23:23-32.
36. Malkin D., Li F.P., Strong L.C., Fraumeni J.F., Nelson C.E., Kim D.H., Kassel J., Gryka M.A., Bischoff F.Z., Tainsky M.A., et al. Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas, and other neoplasms. Science 1990, 250:1233-1238.
37. Mendonca B.B., Lucon A.M., Menezes C.A., Saldanha L.B., Latronico A.C., Zerbini C., Madureira G., Domenice S., Albergaria M.A., Camargo M.H., et al. Clinical, hormonal and pathological findings in a comparative study of adrenocortical neoplasms in childhood and adulthood. J. Urol. 1995, 154:2004-2009.
38. Michalkiewicz E., Sandrini R., Figueiredo B., Miranda E.C., Caran E., Oliveira-Filho A.G., Marques R., Pianovski M.A., Lacerda L., Cristofani L.M., Jenkins J., Rodriguez-Galindo C., Ribeiro R.C. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the International Pediatric Adrenocortical Tumor Registry. J. Clin. Oncol. 2004, 22:838-845.
39. Palmero E.I., Schuler-Faccini L., Caleffi M., Achatz M.I., Olivier M., Martel-Planche G., Marcel V., Aguiar E., Giacomazzi J., Ewald I.P., Giugliani R., Hainaut P., Ashton-Prolla P. Detection of R337H, a germline TP53 mutation predisposing to multiple cancers, in asymptomatic women participating in a breast cancer screening program in Southern Brazil. Cancer Lett. 2008, 261:21-25.
40. Parker K.L., Schimmer B.P. Steroidogenic factor 1: a key determinant of endocrine development and function. Endocr. Rev. 1997, 18:361-377.
41. Peller S., Rotter V. TP53 in hematological cancer: low incidence of mutations with significant clinical relevance. Hum. Mutat. 2003, 21:277-284.
42. Pinto E.M., Billerbeck A.E., Villares M.C., Domenice S., Mendonca B.B., Latronico A.C. Founder effect for the highly prevalent R337H mutation of tumor suppressor p53 in Brazilian patients with adrenocortical tumors. Arq. Bras. Endocrinol. Metab. 2004, 48:647-650.
43. Pinto E.M., Billerbeck A.E., Fragoso M.C., Mendonca B.B., Latronico A.C. Deletion mapping of chromosome 17 in benign and malignant adrenocortical tumors associated with the Arg337His mutation of the p53 tumor suppressor protein. J. Clin. Endocrinol. Metab. 2005, 90:2976-2981.
44. Ragazzon B., Libe R., Gaujoux S., Assie G., Fratticci A., Launay P., Clauser E., Bertagna X., Tissier F., de Reynies A., Bertherat J. Transcriptome analysis reveals that p53 and {beta}-catenin alterations occur in a group of aggressive adrenocortical cancers. Cancer Res. 2010, 70:8276-8281.
45. Reincke M., Karl M., Travis W.H., Mastorakos G., Allolio B., Linehan H.M., Chrousos G.P. P53 mutations in human adrenocortical neoplasms: immunohistochemical and molecular studies. J. Clin. Endocrinol. Metab. 1994, 78:790-794.
46. Ribeiro R.C., Sandrini F., Figueiredo B., Zambetti G.P., Michalkiewicz E., Lafferty A.R., DeLacerda L., Rabin M., Cadwell C., Sampaio G., Cat I., Stratakis C.A., Sandrini R. An inherited p53 mutation that contributes in a tissue-specific manner to pediatric adrenal cortical carcinoma. Proc. Natl. Acad. Sci. USA 2001, 98:9330-9335.
47. Samani A.A., Yakar S., LeRoith D., Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr. Rev. 2007, 28:20-47.
48. Sandrini R., Ribeiro R.C., DeLacerda L. Childhood adrenocortical tumors. J. Clin. Endocrinol. Metab. 1997, 82:2027-2031.
49. Sbiera S., Schmull S., Assie G., Voelker H.U., Kraus L., Beyer M., Ragazzon B., Beuschlein F., Willenberg H.S., Hahner S., Saeger W., Bertherat J., Allolio B., Fassnacht M. High diagnostic and prognostic value of steroidogenic factor-1 expression in adrenal tumors. J. Clin. Endocrinol. Metab. 2010, 95:E161-171.
50. Schuijer M., Berns E.M. TP53 and ovarian cancer. Hum. Mutat. 2003, 21:285-291.
51. Tissier F., Cavard C., Groussin L., Perlemoine K., Fumey G., Hagnere A.M., Rene-Corail F., Jullian E., Gicquel C., Bertagna X., Vacher-Lavenu M.C., Perret C., Bertherat J. Mutations of beta-catenin in adrenocortical tumors: activation of the Wnt signaling pathway is a frequent event in both benign and malignant adrenocortical tumors. Cancer Res. 2005, 65:7622-7627.
52. Varley J.M., McGown G., Thorncroft M., James L.A., Margison G.P., Forster G., Evans D.G., Harris M., Kelsey A.M., Birch J.M. Are there low-penetrance TP53 Alleles? Evidence from childhood adrenocortical tumors. Am. J. Hum. Genet. 1999, 65:995-1006.
53. Vogelstein B., Lane D., Levine A.J. Surfing the p53 network. Nature 2000, 408:307-310.
54. Wajchenberg B.L., Albergaria Pereira M.A., Medonca B.B., Latronico A.C., Campos Carneiro P., Alves V.A., Zerbini M.C., Liberman B., Carlos Gomes G., Kirschner M.A. Adrenocortical carcinoma: clinical and laboratory observations. Cancer 2000, 88:711-736.
55. Weiss L.M. Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors. Am. J. Surg. Pathol. 1984, 8:163-169.
56. West A.N., Ribeiro R.C., Jenkins J., Rodriguez-Galindo C., Figueiredo B.C., Kriwacki R., Zambetti G.P. Identification of a novel germ line variant hotspot mutant p53-R175L in pediatric adrenal cortical carcinoma. Cancer Res. 2006, 66:5056-5062.
57. West A.N., Neale G.A., Pounds S., Figueredo B.C., Rodriguez Galindo C., Pianovski M.A., Oliveira Filho A.G., Malkin D., Lalli E., Ribeiro R., Zambetti G.P. Gene expression profiling of childhood adrenocortical tumors. Cancer Res. 2007, 67:600-608.
58. Wieneke J.A., Thompson L.D., Heffess C.S. Adrenal cortical neoplasms in the pediatric population: a clinicopathologic and immunophenotypic analysis of 83 patients. Am. J. Surg. Pathol. 2003, 27:867-881.
59. Wilkin F., Gagne N., Paquette J., Oligny L.L., Deal C. Pediatric adrenocortical tumors: molecular events leading to insulin-like growth factor II gene overexpression. J. Clin. Endocrinol. Metab. 2000, 85:2048-2056.